{"created":"2023-06-19T11:23:23.649673+00:00","id":3918,"links":{},"metadata":{"_buckets":{"deposit":"c430c0ba-f318-4ec9-9794-3afdaee69200"},"_deposit":{"created_by":3,"id":"3918","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"3918"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:00003918","sets":["7","7:24"]},"author_link":["11815","11816","11817","11818","11819","11820","11821","11822","11823"],"item_5_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3-4","bibliographicPageEnd":"130","bibliographicPageStart":"122","bibliographicVolumeNumber":"90","bibliographic_titles":[{"bibliographic_title":"Life Sciences"}]}]},"item_5_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aims: Cirrhotic patients commonly have a liver zinc deficiency, which may aggravate liver fibrosis due to the lack of antioxidative effects of zinc. This study examined the ability of polaprezinc, N-(3-aminopropionyl)-Lhistidinato zinc, to prevent fibrosis in a rat model of thioacetamide (TAA)-induced hepatic fibrosis.  Main methods: Liver cirrhosis was induced by orally administering TAA for 20 weeks. The rats were cotreated with one of the following for the last 10 weeks of TAA treatment: (1) polaprezinc (50 or 200 mg/kg/day); (2) L-carnosine (155 mg/kg/day),which contained equal amounts of L-carnosine as 200 mg/kg/day polaprezinc; (3) zinc sulfate (112 mg/kg/day) or (4) zinc-L-aspartic complex (317.8 mg/kg/day). Both zinc supplementations contained equal amounts of zinc as high-dose polaprezinc.  Key findings: Hepatic zinc levels fell significantly in rats treated with TAA for 20 weeks. Cotreating with high-dose polaprezinc and zinc-L-aspartic complex for 10 weeks prevented hepatic zinc loss. Hepatic hydroxyproline and tissue inhibitor of metalloproteinases-1 (TIMP-1) were significantly higher in rats treated with TAA for 20 weeks than 10 weeks, whereas polaprezinc prevented changes in these fibrosis markers and reduced hepatic transforming growth factor-β1 protein concentration, macroscopic and histologic changes. TAA caused oxidative stress-related changes in the liver that were prevented by high-dose polaprezinc and partially by zinc-L-aspartic complex. Treatment with L-carnosine, low-dose polaprezinc or zinc sulfate for 10 weeks did not affect liver fibrosis progression or oxidative stress-related changes.  Significance: Polaprezincmay prevent ongoing fibrosis by preventing zinc depletion, oxidative stress and fibrosis markers in cirrhotic livers.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_description_36":{"attribute_name":"注記","attribute_value_mlt":[{"subitem_description":"Author","subitem_description_type":"Other"}]},"item_5_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"text","subitem_description_type":"Other"}]},"item_5_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_5_relation_24":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.lfs.2011.10.022","subitem_relation_type_select":"DOI"}}]},"item_5_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0024-3205","subitem_source_identifier_type":"PISSN"}]},"item_5_text_44":{"attribute_name":"ID(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"22100444"}]},"item_5_text_54":{"attribute_name":"閲覧数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"1010"}]},"item_5_text_55":{"attribute_name":"ダウンロード数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"1387"}]},"item_5_version_type_38":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"河野, 透","creatorNameLang":"ja"},{"creatorName":"コウノ, トオル","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"11815","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Asama, Toshiyuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11816","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chisato, Naoyuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11817","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ebisawa, Yoshiaki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11818","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okayama, Taishi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11819","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Imai, Koji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11820","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Karasaki, Hidenori","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11821","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Hiroyuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11822","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoneda, Masashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11823","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-07-06"}],"displaytype":"detail","filename":"4639.pdf","filesize":[{"value":"1.7 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"4639.pdf","url":"https://asahikawa-med.repo.nii.ac.jp/record/3918/files/4639.pdf"},"version_id":"e4a52a7f-6c41-4b04-b423-988a96293e4f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Zinc","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Fibrosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Polaprezinc","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cirrhosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Amino acid complex","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats.","subitem_title_language":"en"}]},"item_type_id":"5","owner":"3","path":["6","7","24"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2012-07-02"},"publish_date":"2012-07-02","publish_status":"0","recid":"3918","relation_version_is_last":true,"title":["Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats."],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2024-07-26T08:34:30.839119+00:00"}